As a critical negative regulator of the JAK-STAT pathway, PTPN2 functions to directly regulate signaling through cytokine receptors, including IFNγ. Thus, enhancing IFNγ sensing and signaling through the inhibition of PTPN2 is a potential therapeutic strategy to improve the efficacy of cancer immunotherapy regimens.

Mondego’s drug candidate  demonstrates strong PTPN2/PTPN1 inhibitory activity, outstanding selectivity against all other phosphatases, and exhibit high oral bioavailability and good safety profiles; inducing tumor cells’ susceptibility to IFNγ and suppressing  their growth with high efficacy.